We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI Algorithm Combined With Blood Test Quickly and Accurately Diagnoses Heart Attacks in Women

By LabMedica International staff writers
Posted on 05 Sep 2022

Previous research has shown that women in the UK who have a heart attack receive poorer care than men at every stage. More...

Women were 50% more likely to receive a wrong initial diagnosis, highlighting the need for innovations to help close the heart attack gender gap. Measuring the protein troponin in the blood is the current gold standard for diagnosing a heart attack. However, the levels of troponin released by the heart vary between men and women, with age and other health conditions. Current guidelines use the same threshold for all patients, meaning current tests are not as accurate as they could be. Now, an algorithm developed using artificial intelligence (AI) could help doctors to diagnose heart attacks in women more accurately and quicker than ever before.

Researchers at the University of Edinburgh (Edinburgh, Scotland) combined data from 10,038 people (48% women) who went to hospital with a suspected heart attack to develop an AI-based tool to help clinicians diagnose heart attacks more accurately. They then validated it on a further 3,035 people (31% women) outside of the UK. The tool, called CoDE-ACS, uses AI to combine routinely collected patient information when they arrive at hospital (including sex, age, observations, ECG findings and medical history) with the results from the troponin blood test. This then produces a score of 0 to 100.

The team found that CoDE-ACS was able to rule out a heart attack with 99.5% accuracy, confirming they were safe to go home. It also identified those who would benefit from staying in hospital for further tests, in whom the final diagnosis was a heart attack, with an accuracy of 83.7%. This compares to an accuracy of just 49.4% with current tests. Fewer than half of those identified for further testing using current approaches had a diagnosis of heart attack. The performance of the tool was consistent regardless of sex, age and pre-existing health conditions. Current tests mean that some patients’ troponin levels do not fit into the ‘rule in’ or ‘rule out’ thresholds, making clinical decisions more challenging. However, with a second troponin measurement, CoDE-ACS was able refine risk in the 29.5% of people who did not fit the simple ‘rule in’ or ‘rule out’ criteria allowing accurate determination if further action was needed.

“This is a huge step forward which promises to ensure everyone is on a level playing field when it comes to heart attack diagnosis and treatment,” said Professor James Leiper, our Associate Medical Director. “We know that women are more likely to receive a misdiagnosis, but by harnessing the power of AI, this team could provide one solution that helps to make that an issue of the past.”

“We’ve now embedded our algorithm into an easy-to-use mobile app to support doctors in guiding treatment decisions,” said Dimitrios Doudesis, data scientist at the BHF Centre for Cardiovascular Science, University of Edinburgh. “Whilst the troponin test takes 30 minutes to process, we take an array of other health information and add it into the app alongside the troponin measurement. This provides doctors with a precise and instantaneous score to confirm if they can reassure their patient that they haven’t had a heart attack and send them home, or if they require further tests.”

Related Links:
University of Edinburgh


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
POC Immunoassay Analyzer
Procise DX
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring

Hepatitis D virus infection can accelerate progression to cirrhosis and liver cancer, making timely diagnosis and longitudinal monitoring essential. Because hepatitis D depends on co-infection or superinfection... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.